GlassScriptPhysician profile
Karla R Smith
NPI 1275663593
$9,925.88
in general payments reported to CMS, 2019-2025
53 companies · $836 in 2025
The $836 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $761 · 2021: $2,003 · 2022: $2,126 · 2023: $1,587 · 2024: $1,287 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,710.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,225.10 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Lilly USA, LLC | $1,296.76 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,149.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $888.84 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $542.75 | 2019-2025 | |
| Preventric Diagnostics, INC. | $383.37 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $345.53 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.75 | 2020-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $257.59 | 2019-2025 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $224.86 | 2019-2022 | |
| Genentech USA, INC. | $179.87 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $155.68 | 2022-2023 | Linzess |
| Astellas Pharma US INC | $150.73 | 2019-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $129.28 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $126.98 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.